A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes
Eine randomisierte, doppelmaskierte Crossover-Studie eines GPR119-Agonisten zur Glukagon-Konterregulation bei Hypoglykämie bei Typ-1-Diabetes
Diabetes · 01.07.2025 · 74 (7) · 1262-1272
DOI: 10.2337/db25-0096 ↗Auf einen Blick
Bei 18 Personen mit Typ-1-Diabetes verbesserte MBX-2982 die Glukagon-Konterregulation während experimenteller Hypoglykämie nicht gegenüber Placebo. Die GLP-1-Antwort im MMT war unter MBX-2982 um 17 % höher.
Fragestellung
Verbessert MBX-2982 als GPR119-Agonist die counterregulatorische Antwort auf experimentelle Hypoglykämie bei Typ-1-Diabetes?
Methode
Phase-2a-Studie, doppelmaskiert, Crossover; 18 Teilnehmende mit Typ-1-Diabetes, 600 mg MBX-2982 oder Placebo täglich für 14 Tage, 2-wöchige Washout-Phase.
Ergebnisse
Maximale Glukagonantwort, Glukagon-AUC und inkrementelle AUC unterschieden sich nicht zwischen MBX-2982 und Placebo. Auch Epinephrin, Norepinephrin, pankreatisches Polypeptid, freie Fettsäuren und endogene Glukoseproduktion waren unverändert.
Schlussfolgerung der Autor:innen
Die Aktivierung von GPR119 mit MBX-2982 verbesserte die counterregulatorischen Antworten auf Hypoglykämie bei Typ-1-Diabetes nicht. Die GLP-1-Anstiege sprechen für Target-Engagement und eine erwartete pharmakodynamische Antwort.
Kernaussagen
- 18 Personen mit Typ-1-Diabetes in einer Phase-2a-Crossover-Studie
- Keine Verbesserung der Glukagon-Konterregulation unter MBX-2982
- GLP-1 im MMT unter MBX-2982 um 17 % höher
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, online erschienen am 02.04.2025. Verfasst von Anika Bilal und 9 weiteren Autor:innen. Beteiligte Einrichtung: AdventHealth Translational Research Institute, Orlando, FL. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Hypoglycemia, Receptors, G-Protein-Coupled, Glucagon. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Activation of GPR119 receptors, expressed on enteroendocrine and pancreatic islet cells, augments glucagon counterregulatory responses to hypoglycemia in preclinical models. We hypothesized that MBX-2982, a GPR119 agonist, would augment counterregulatory responses to experimental hypoglycemia in participants with type 1 diabetes (T1D). To assess this, we designed a phase 2a, double-masked, crossover trial in 18 participants (age 20–60 years) with T1D. Participants were randomized to treatment with 600 mg MBX-2982 or placebo daily for 14 days, with a 2-week washout between treatments. Counterregulatory responses to hypoglycemia during a hyperinsulinemic euglycemic-hypoglycemic clamp and hormonal responses during a mixed-meal test (MMT) were measured. The maximum glucagon response, glucagon area under the curve (AUC), and incremental AUC were not significantly different during MBX-2982 versus placebo treatment. MBX-2982 did not alter epinephrine, norepinephrine, pancreatic polypeptide, free fatty acid, or endogenous glucose production responses to hypoglycemia compared with placebo. However, glucagon-like peptide 1 (GLP-1) response during the MMT was 17% higher with MBX-2982 compared with placebo treatment. In conclusion, GPR119 activation with MBX-2982 did not improve counterregulatory responses to hypoglycemia in people with T1D. Increases in GLP-1 during the MMT are consistent with GPR119 target engagement and the expected pharmacodynamic response from L cells. Article Highlights Hypoglycemia is the limiting factor for optimal glycemic control in people with type 1 diabetes (T1D). Activation of α-cell GPR119 receptors increases glucagon counterregulatory responses to hypoglycemia in preclinical studies. We assessed the effect of MBX-2982, a GPR119 agonist, on glucagon counterregulatory responses to experimental hypoglycemia in participants with T1D. Activation of GPR119 with MBX-2982 did not improve glucagon counterregulatory responses to hypoglycemia in participants with T1D, though increases in fasting glucagon-like peptide 1 and responses during a mixed-meal test demonstrated appropriate target engagement. GPR119 agonists are unlikely to be effective agents to mitigate hypoglycemia risk in people with T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- AdventHealth Translational Research Institute, Orlando, FL.
- Jaeb Center for Health Research, Tampa, FL.
- ProSciento, Inc., San Diego, CA.
- Cardiometabolic Diseases, Merck Research Laboratories, Rahway, NJ.
- AdventHealth Diabetes Institute, Orlando, FL.
ORCID-Profile: Anika Bilal, Marcus Hompesch
Förderung
- Leona M. and Harry B. Helmsley Charitable Trust
Zitieren
APA
Bilal, A., Casu, A., Yi, F., Dutta, T., Mucinski, J. M., Mercouffer, G., Marak, M. C., Hompesch, M., Kelley, D., & Pratley, R. E. (2025). A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes. Diabetes, 74(7), 1262-1272. https://doi.org/10.2337/db25-0096
Vancouver
Bilal A, Casu A, Yi F, Dutta T, Mucinski JM, Mercouffer G, et al. A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes. Diabetes. 2025;74(7):1262-1272. doi:10.2337/db25-0096
BibTeX
@article{Bilal2025,
author = {Bilal, Anika and Casu, Anna and Yi, Fanchao and Dutta, Tumpa and Mucinski, Justine M and Mercouffer, Gina and Marak, Martin C and Hompesch, Marcus and Kelley, David and Pratley, Richard E},
title = {A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes},
journal = {Diabetes},
year = {2025},
volume = {74},
number = {7},
pages = {1262--1272},
doi = {10.2337/db25-0096}
}
EUVIMED